{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:40:28Z","timestamp":1782315628435,"version":"3.54.5"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and morbidity in individuals with type 2 diabetes mellitus (T2DM). Accordingly, several scientific societies have released clinical practice guidelines to assist health professionals in ASCVD risk management in patients with T2DM. However, some recommendations differ from each other, contributing to uncertainty about the optimal clinical management of patients with T2DM and established ASCVD or at high risk for ASCVD. Thus, the purpose of this paper is to discuss recent evidence-based guidelines on ASCVD risk stratification and prevention in patients with T2DM, in terms of disparities and similarities. To close the gap between different guidelines, a multidisciplinary approach involving general practitioners, endocrinologists, and cardiologists may enhance the coordination of diagnosis, therapy, and long-term follow-up of ASCVD in patients with T2DM.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1227769","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T09:49:54Z","timestamp":1695808194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines"],"prefix":"10.3389","volume":"10","author":[{"given":"Pierre","family":"Gourdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Schiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Halimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Kownator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Valensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1161\/circulationaha.118.035408","article-title":"Progress toward improved cardiovascular health in the United States","volume":"139","author":"Pahigiannis","year":"2019","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5551\/jat.RV17014","article-title":"Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus","volume":"25","author":"Katakami","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/ijms21051835","article-title":"The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation","volume":"21","author":"Poznyak","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/circresaha.121.319811","article-title":"Social determinants of cardiovascular disease","volume":"130","author":"Powell-Wiley","year":"2022","journal-title":"Circ Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/circulationaha.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus\u2014mechanisms, management, and clinical considerations","volume":"133","author":"Wang CC","year":"2016","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","article-title":"Cardiovascular complications of diabetic kidney disease","volume":"21","author":"P\u00e1lsson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"B8","first-page":"13","article-title":"The interplay between diabetes, cardiovascular disease, and kidney disease","volume-title":"Chronic kidney disease and type 2 diabetes","author":"Usman","year":"2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1161\/cir.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.2337\/dci19-0036","article-title":"The 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APHA\/ASPC\/NLA\/PCNA guidelines on the management of blood cholesterol in diabetes","volume":"43","author":"Goldberg","year":"2020","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"101185","DOI":"10.1016\/j.diabet.2020.08.002","article-title":"Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: position paper of the French Society of Cardiology and the French-Speaking Society of Diabetology","volume":"47","author":"Valensi","year":"2021","journal-title":"Diabetes Metab"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1177\/2047487319846715","article-title":"Risk prediction tools in cardiovascular disease prevention: a report from the ESC prevention of CVD programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP)","volume":"26","author":"Rossello","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/cir.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.4158\/cs-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College Of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm\u20142020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/cs-2019-0472","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142020 executive summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"B18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jcjd.2020.08.001","article-title":"Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update","volume":"44","author":"Lipscombe","year":"2020","journal-title":"Can J Diabetes"},{"key":"B19","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1016\/j.jacc.2016.02.055","article-title":"Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population","volume":"67","author":"Rana","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/eurheartj\/ehw301","article-title":"Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-atherosclerotic cardiovascular disease risk score in a modern multi-ethnic cohort","volume":"38","author":"DeFilippis","year":"2017","journal-title":"Eur Heart J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.2337\/dc09-0745","article-title":"Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: the Hoorn study","volume":"32","author":"van der Heijden","year":"2009","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/1741826710394270","article-title":"Contemporary model for cardiovascular risk prediction in people with type 2 diabetes","volume":"18","author":"Kengne","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"B25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.5830\/cvja-2013-078","article-title":"The advance cardiovascular risk model and current strategies for cardiovascular disease risk evaluation in people with diabetes","volume":"24","author":"Kengne","year":"2013","journal-title":"Cardiovasc J Afr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2014new world-wide definition. A consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.5114\/aoms.2019.89449","article-title":"Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!","volume":"15","author":"Katsiki","year":"2019","journal-title":"Arch Med Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100335","DOI":"10.1016\/j.ajpc.2022.100335","article-title":"Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement","volume":"10","author":"Wong","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1161\/circulationaha.119.045010","article-title":"Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular disease in 2019: the mesa study (multi-ethnic study of atherosclerosis)","volume":"141","author":"Cainzos-Achirica","year":"2020","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e003528","DOI":"10.1161\/circimaging.115.003528","article-title":"Absence of coronary artery calcium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients","volume":"9","author":"Valenti","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"B32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jcmg.2020.06.047","article-title":"Predicting long-term absence of coronary artery calcium in metabolic syndrome and diabetes: the mesa study","volume":"14","author":"Razavi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"B33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1161\/circulationaha.105.580696","article-title":"Distribution of coronary artery calcium by race, gender, and age: results from the multi-ethnic study of atherosclerosis (MESA)","volume":"113","author":"McClelland","year":"2006","journal-title":"Circulation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2337\/dc11-0816","article-title":"Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: the multi-ethnic study of atherosclerosis","volume":"34","author":"Malik","year":"2011","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.diabet.2022.101412","article-title":"Clinical relevance of coronary risk classification and reclassification with coronary artery calcium score in asymptomatic people living with diabetes. An observational study","volume":"49","author":"Cosson","year":"2022","journal-title":"Diabetes Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-023-01760-4","article-title":"Performance of the 2019 ESC\/EASD guideline strategy for the screening of silent coronary artery disease in patients with diabetes","volume":"22","author":"Valensi","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e200484","DOI":"10.1148\/ryct.2021200484","article-title":"An update on coronary artery calcium interpretation at chest and cardiac CT","volume":"3","author":"Obisesan","year":"2021","journal-title":"Radiol Cardiothorac Imaging"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2337\/dc08-9021","article-title":"Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists","volume":"31","author":"Boulton","year":"2008","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s00125-018-4642-y","article-title":"Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study","volume":"61","author":"Oellgaard","year":"2018","journal-title":"Diabetologia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e2148030","DOI":"10.1001\/jamanetworkopen.2021.48030","article-title":"Use of lipid-, blood pressure-, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease","volume":"5","author":"Nelson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12933-021-01258-x","article-title":"Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","volume":"20","author":"Lugner","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/circulationaha.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (rewind): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: deliver trial","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMc1611290","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/s0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/s2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with glp-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/circulationaha.121.057934","article-title":"Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the amplitude-O trial","volume":"145","author":"Lam","year":"2022","journal-title":"Circulation"},{"key":"B65","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2337\/ds19-0031","article-title":"Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes","volume":"33","author":"Anderson","year":"2020","journal-title":"Diabetes Spectr"},{"key":"B66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.diabet.2019.07.007","article-title":"Type 2 diabetes: why should diabetologists and cardiologists work more closely together?","volume":"45","author":"Valensi","year":"2019","journal-title":"Diabetes Metab"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1227769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T09:49:57Z","timestamp":1695808197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1227769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":67,"alternative-id":["10.3389\/fcvm.2023.1227769"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1227769","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"article-number":"1227769"}}